The company has no franking or imputation credits as of their last full year report. Paying a 50c diviend to share holders that isn't franked would be a strange decision when there's an active buyback which is much better for our potential total return.
https://www.neurenpharma.com/pdf/7fa054fc-98c4-4a0a-81fc-c6aac3f42b86/Appendix-4E-and-2023-full-year-accounts.pdf
We don't yet have the 2024 full year report so perhaps they now have the sufficent franking credits but I still maintain that would be an odd decision and all commentary from Jon seems to suggest that a dividend is unlikely.
The company has no franking or imputation credits as of their...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$14.20 |
Change
0.890(6.69%) |
Mkt cap ! $1.761B | |||
| Open | High | Low | Value | Volume |
| $13.50 | $14.26 | $12.96 | $9.111M | 655.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2000 | $14.17 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.23 | 3278 | 1 |
View Market Depth
| Last trade - 16.15pm 27/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |